Michael Krainer
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 34
- HER2/EGFR in Cancer Research 8
- Cancer Cells and Metastasis 7
- Cancer Treatment and Pharmacology 6
- Co-authors
- Dietmar Pils (18 shared papers)Christoph Carl Zielinski (26 shared papers)Peter Horak (22 shared papers)Robert Zeillinger (22 shared papers)Daniel A. Haber (6 shared papers)Reinhard Horvat (12 shared papers)Elke Fritz (4 shared papers)Kurt J. Isselbacher (4 shared papers)
- Journals
- European Journal of Cancer (9 papers)Annals of Oncology (5 papers)Cancer (5 papers)Gynecologic Oncology (4 papers)Blood (4 papers)
- Partner nations
- AustriaUnited StatesFrance
In The Last Decade
Michael Krainer
109 papers receiving 5.7k citations
Michael Krainer's Hit Papers
Peers
Comparison fields: 5 of 114
- Oncology 2.5k
- Immunology 1.3k
- Cancer Research 858
- Hematology 461
- Pulmonary and Respiratory Medicine 1.2k
Countries citing papers authored by Michael Krainer
This map shows the geographic impact of Michael Krainer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Krainer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Krainer more than expected).
Fields of papers citing papers by Michael Krainer
This network shows the impact of papers produced by Michael Krainer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Krainer. The network helps show where Michael Krainer may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Krainer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2014 | 1259 |
| 2 | 1998 | 447 | |
| 3 | 1996 | 328 | |
| 4 | 1996 | 265 | |
| 5 | 2016 | 212 | |
| 6 | 2009 | 191 | |
| 7 | 1997 | 179 | |
| 8 | 2020 | 146 | |
| 9 | 1991 | 135 | |
| 10 | 2004 | 125 | |
| 11 | 2005 | 125 | |
| 12 | 1991 | 116 | |
| 13 | 2010 | 99 | |
| 14 | 2014 | 84 | |
| 15 | 2005 | 82 | |
| 16 | 1993 | 79 | |
| 17 | 2006 | 78 | |
| 18 | Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. | 1991 | 75 |
| 19 | 2007 | 74 | |
| 20 | 2022 | 74 |
About Michael Krainer
Michael Krainer is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Hematology, having authored 110 papers that have together received 5.9k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (16 papers), Cell death mechanisms and regulation (10 papers), HER2/EGFR in Cancer Research (8 papers), Multiple Myeloma Research and Treatments (7 papers), Cancer Cells and Metastasis (7 papers), Cancer Treatment and Pharmacology (6 papers), DNA Repair Mechanisms (6 papers) and BRCA gene mutations in cancer (6 papers). The work is most often cited by research in Oncology (2.5k citations), Immunology (1.3k citations), Cancer Research (858 citations), Hematology (461 citations) and Pulmonary and Respiratory Medicine (1.2k citations). Michael Krainer has collaborated with scholars based in Austria, United States and France. Frequent co-authors include Dietmar Pils, Christoph Carl Zielinski, Peter Horak, Robert Zeillinger, Daniel A. Haber, Reinhard Horvat, Elke Fritz, Kurt J. Isselbacher, Michael G. FitzGerald and Christoph Wiltschke. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Cancer, Gynecologic Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.